SCHEMBL29333419

SCHEMBL29333419

C=CC(=O)N1CCOCC1c1cc(Cl)cc(-c2ccc3nccnc3c2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNC P24863 1/20 0.38
▸ CDK8 P49336 1/20 0.38
▸ CCKBR P32239 2/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ CYP3A4 P08684 3/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ CYP2C9 P11712 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ BTK Q06187 4/20 0.33
▸ EGFR P00533 2/20 0.33
▸ BMX P51813 2/20 0.33
▸ ITK Q08881 2/20 0.33
▸ SCD5 Q86SK9 1/20 0.33
▸ TGFBR1 P36897 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ HCRTR1 O43613 2/20 0.32
▸ HCRTR2 O43614 2/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31008586 1.00 CCNC (0.38) CCNCCDK8CCKBRGRIN2BCYP3A4
SCHEMBL29333422 0.89 GRIN2B (0.35) CCNCCDK8CCKBRGRIN2BCYP3A4
SCHEMBL30855178 0.87 BTK (0.36) CCNCCDK8CYP3A4BTKEGFR
SCHEMBL29333566 0.87 BTK (0.36) CCNCCDK8CYP3A4BTKEGFR
SCHEMBL29333552 0.85 MAPK1 (0.40) CCNCCDK8CYP3A4BTKEGFR
SCHEMBL29333508 0.85 CCNC (0.38) CCNCCDK8GRIN2BCYP3A4BTK
SCHEMBL31008617 0.85 BTK (0.39) CCNCCDK8BTKEGFRBMX
SCHEMBL29333480 0.85 BTK (0.39) CCNCCDK8BTKEGFRBMX
SCHEMBL31008642 0.85 CCNC (0.38) CCNCCDK8GRIN2BCYP3A4BTK
SCHEMBL31008584 0.83 HCRTR1 (0.39) CCNCCDK8CYP3A4BTKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 CCNC 4349/4885CDK8 1776/4885CCKBR 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback